CRSP250117C90000
- 0.05
- 0.000.00%
CRISPR Therapeutics Newsroom
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Cuts Target Price to $30
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Are up 7.1% This Past Week, but Still in the Red Over the Last Year
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Trump's HHS Pick RFK Jr. to Face Key Senate Hearings Next Week
Bargain Basement CRISPR Therapeutics Becomes Takeover Target
CRISPR Therapeutics Stock Pops Following Disclosure of RFK Jr. Investment
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia
CRISPR Therapeutics AG (CRSP): The Biotech Stock With Biggest Upside Potential
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Cathie Wood's ARK Invest Boosts CRISPR Therapeutics (NASDAQ:CRSP) Stake
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Promising Developments and Strategic Partnerships Drive Crispr Therapeutics' Growth Potential
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $85
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?